Aurora C Inhibitor

Reversine is a novel class of ATP-competitive Aurora kinase inhibitor with IC₅₀s of 400, 500 and 400 nM for Aurora A, Aurora B and Aurora C, respectively.

Tozasertib (VX 680; MK-0457) is an inhibitor of Aurora A/B/C kinases with K_is of 0.6, 18, 4.6 nM, respectively.

Danusertib is a pyrrolo-pyrazole and aurora kinase inhibitor with IC₅₀ of 13, 79, and 61 nM for Aurora A, B, and C, respectively.

AMG 900 is a potent and highly selective pan-Aurora kinases inhibitor with IC₅₀ of 5 nM, 4 nM and 1 nM for Aurora A, B and C, respectively.

GSK-1070916 is a potent and selective ATP-competitive inhibitor of aurora B and aurora C with K_is of 0.38 and 1.5 nM, respectively, and is >250- fold selective over Aurora A.

SNS-314 mesylate is a potent and selective aurora kinase inhibitor with IC₅₀s of 9, 31, and 6 nM for aurora A, B and C, respectively.

CCT 137690 is a potent and orally available aurora kinase inhibitor with IC₅₀s of 15, 25, and 19 nM for aurora A, B and C, respectively.

Ilorasertib (ABT-348) is a potent, orally active and ATP-competitive aurora inhibitor with IC₅₀s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib also is a potent VEGF, PDGF inhibitor. Ilorasertib has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

BI-847325 is an ATP competitive dual inhibitor of MEK and aurora kinases (AK) with IC₅₀ values of 4 and 15 nM for human MEK2 and AK-C, respectively. BI-847325 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

PHA-680632 is an aurora kinase inhibitor with IC₅₀s of 27, 135 and 120 nM for aurora A, B and C, respectively.

CCT129202 is an aurora kinase inhibitor with IC₅₀s of 42, 198, and 227 nM for aurora A, B and C, respectively.

Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC₅₀s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib hydrochloride also is a potent VEGF, PDGF inhibitor. Ilorasertib hydrochloride has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

SNS-314 is a potent and selective aurora kinase inhibitor with IC₅₀s of 9, 31, and 6 nM for aurora A, B and C, respectively.

XMD-12 (compound 1) is an Aurora kinase (Aurora Kinase) inhibitor with anti-tumor activity that promotes paclitaxel (HY-B0015) induced cell death. XMD-12 exhibits high selectivity and potency against Aurora A, B, and C kinases, with IC₅₀ values of 5.6, 18.4, and 24.6 nM, respectively.

BRD-7880 is a potent and highly specific inhibitor of Aurora Kinase B (AURKB) and Aurora Kinase C (AURKC), with IC₅₀ values of 7 nM and 12 nM, respectively.